{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T09:46:48Z","timestamp":1782380808996,"version":"3.54.5"},"reference-count":26,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is an adult-onset inflammatory disorder caused by acquired mutations in UBA1, the gene encoding the primary ubiquitin-activating enzyme. The recognition of VEXAS has transformed the current understanding of autoinflammatory disease by demonstrating that somatic alterations arising within hematopoietic stem cells can precipitate severe, multisystem inflammation in later life. While pathogenic UBA1 variants are essential to disease pathogenesis, many affected individuals also harbor additional somatic mutations associated with clonal hematopoiesis, most commonly involving DNMT3A and TET2. These concurrent mutations may contribute to clonal architecture; however, their independent impact on inflammatory phenotype and hematologic manifestations remains incompletely defined. Emerging evidence suggests that co-occurring clonal hematopoiesis mutations may be independently associated with poorer overall survival, though their causal role remains unestablished. This review examines the evolving genetic framework of VEXAS syndrome, emphasizing UBA1 as the obligate driver mutation while reviewing current evidence regarding non-Met41 UBA1 variants and co-occurring somatic mutations.<\/jats:p>","DOI":"10.3390\/genes17060711","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T08:14:12Z","timestamp":1782375252000},"page":"711","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["VEXAS Syndrome Beyond UBA1: Genetic Architecture and the Role of Co-Occurring Somatic Mutations\u2014A Focused Review"],"prefix":"10.3390","volume":"17","author":[{"given":"Konstantin N.","family":"Konstantinov","sequence":"first","affiliation":[{"name":"Medicine Service, Section of Rheumatology, Raymond G. Murphy VA Medical Center, Albuquerque, NM 87108, USA"},{"name":"Department of Medicine, University of New Mexico, Albuquerque, NM 87131, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikifor K.","family":"Konstantinov","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of New Mexico, Albuquerque, NM 87131, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5694-9130","authenticated-orcid":false,"given":"Vijayalakshmi","family":"Kumar","sequence":"additional","affiliation":[{"name":"Medicine Service, Section of Rheumatology, Raymond G. Murphy VA Medical Center, Albuquerque, NM 87108, USA"},{"name":"Department of Medicine, University of New Mexico, Albuquerque, NM 87131, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","article-title":"Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease","volume":"383","author":"Beck","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_2","first-page":"244","article-title":"Spectrum of clonal hematopoiesis in VEXAS syndrome","volume":"142","author":"Kusne","year":"2023","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1182\/blood.2020010286","article-title":"Novel somatic mutations in UBA1 as a cause of VEXAS syndrome","volume":"137","author":"Poulter","year":"2021","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1055\/s-0043-1770958","article-title":"VEXAS syndrome\u2014Review","volume":"10","author":"Zhang","year":"2023","journal-title":"Glob. Med. Genet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(25)02164-6","article-title":"VEXAS syndrome: A comprehensive review of pathogenesis, clinical spectrum, and therapeutic strategies","volume":"407","author":"Groarke","year":"2026","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Jawad, M., Afkhami, M., Ding, Y., Zhang, X., Li, P., Young, K., Xu, M.L., Cui, W., Zhao, Y., and Halene, S. (2022). DNMT3A R882 mutations confer unique clinicopathologic features in myelodysplastic syndromes. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.849376"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/16078454.2019.1657613","article-title":"Prognostic value of DNMT3A mutations in myelodysplastic syndromes: A meta-analysis","volume":"24","author":"Liang","year":"2019","journal-title":"Hematology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/mrcr\/rxab021","article-title":"UBA1 and DNMT3A mutations in VEXAS syndrome: A case report and literature review","volume":"6","author":"Shaukat","year":"2022","journal-title":"Mod. Rheumatol. Case Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"11410","DOI":"10.1182\/blood-2022-167359","article-title":"DNMT3A\/TET2 mutant clonal hematopoiesis in VEXAS syndrome results in DNA hypomethylation and transcriptional activation of WT1 and MPL oncogenic pathways","volume":"140","author":"Fernandez","year":"2022","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"L\u00f6tscher, F., Seitz, L., Simeunovic, H., Sarbu, A.C., Porret, N., Feldmeyer, L., Recher, M., Balabanov, S., Tzankov, A., and Daskalakis, M. (2022). Genetic double strike: VEXAS and TET2-positive myelodysplastic syndrome. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.800149"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/s41375-023-01857-5","article-title":"Novel causative variants of VEXAS in UBA1 detected through whole genome transcriptome sequencing in a large cohort of hematological malignancies","volume":"37","author":"Sakuma","year":"2023","journal-title":"Leukemia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1038\/s41375-025-02775-4","article-title":"Distinct characteristics of VEXAS-causative UBA1 M41 and recurrent functional non-M41 mutations","volume":"39","author":"Sakuma","year":"2025","journal-title":"Leukemia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1182\/blood.2023023723","article-title":"Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes","volume":"144","author":"Sirenko","year":"2024","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/s41591-025-03623-9","article-title":"Mechanisms of hematopoietic clonal dominance in VEXAS syndrome","volume":"31","author":"Molteni","year":"2025","journal-title":"Nat. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s41584-025-01270-5","article-title":"Clonal dominance: Mutations in VEXAS syndrome take advantage of inflammation","volume":"21","author":"Magaziner","year":"2025","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1182\/blood.2022016985","article-title":"Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis","volume":"140","author":"Ferrada","year":"2022","journal-title":"Blood"},{"key":"ref_18","unstructured":"National Comprehensive Cancer Network (2026). Myelodysplastic Syndromes, Version 3.2026, National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Corrao, S., Moschetti, M., Scibetta, S., Zizzo, C., Calvo, L., Giardina, A., Cangemi, I., Colomba, P., Duro, G., and Novo, G. (2025). VEXAS syndrome: Genetics, gender differences, clinical insights, diagnostic pitfalls, and emerging therapies. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26167931"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/joim.70023","article-title":"Characterizing VEXAS syndrome in women: Findings from an international multicenter study","volume":"298","author":"Bourguiba","year":"2025","journal-title":"J. Intern. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/art.43287","article-title":"American College of Rheumatology guidance statement for diagnosis and management of VEXAS syndrome developed by the International VEXAS Working Group expert panel","volume":"78","author":"Mekinian","year":"2025","journal-title":"Arthritis Rheumatol."},{"key":"ref_22","first-page":"3591","article-title":"VEXAS syndrome","volume":"137","author":"Grayson","year":"2021","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1182\/blood.2024028133","article-title":"Efficacy and safety of azacitidine for VEXAS syndrome: A large-scale retrospective study from FRENVEX","volume":"146","author":"Jachiet","year":"2025","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"644","DOI":"10.18632\/oncotarget.28646","article-title":"UBA1 dysfunction in VEXAS and cancer","volume":"15","author":"Sakuma","year":"2024","journal-title":"Oncotarget"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1007\/s10067-024-07160-7","article-title":"Allogeneic haematopoietic stem cell transplantation in VEXAS: A review of 33 patients","volume":"43","author":"Ali","year":"2024","journal-title":"Clin. Rheumatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s10875-025-01932-9","article-title":"Diagnostic and monitoring strategies for VEXAS syndrome: Evaluating Sanger sequencing, NGS, and the SWIM-score","volume":"45","author":"Dyrmose","year":"2025","journal-title":"J. Clin. Immunol."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/17\/6\/711\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T08:58:16Z","timestamp":1782377896000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/17\/6\/711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,20]]},"references-count":26,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["genes17060711"],"URL":"https:\/\/doi.org\/10.3390\/genes17060711","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,20]]}}}